Suven Pharmaceuticals Analyst Review May 2026
- May 21, 2026
- Posted by: Neeraj Pandey
- Category: News
This Suven Pharmaceuticals analyst review for May 2026 covers the key data investors need for SUVENPHAR at its current price of Rs 1,250. Suven Pharmaceuticals (NSE: SUVENPHAR) is a pharmaceutical CDMO company with a market capitalisation of approximately Rs 8,500 crore, specialising in CNS (central nervous system) and specialty molecule synthesis. The analyst consensus target of Rs 1,550 implies meaningful upside, and this Suven Pharmaceuticals analyst review examines technical levels, business performance, valuation, and key risks for SUVENPHAR through FY27.
Click Here – Get Free Investment Predictions
Suven Pharmaceuticals Company Snapshot May 2026
Suven Pharmaceuticals’ CDMO services for global pharma innovators in CNS, oncology, and metabolic diseases provide high-value, long-duration service contracts. Zero-debt and above 40 percent EBITDA margins underpin quality. The table below summarises the key data referenced in this Suven Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | SUVENPHAR |
| Sector | Pharmaceuticals – CDMO |
| CMP (May 2026) | Rs 1,250 |
| 52 Week High | Rs 1,650 |
| 52 Week Low | Rs 1,050 |
| Market Cap | Rs 8,500 Crore |
| Trailing P/E | 45x |
| Analyst Consensus Target | Rs 1,550 |
| Bull Case Target | Rs 1,900 |
| Bear Case Target | Rs 1,000 |
Analyst Insight in This Suven Pharmaceuticals Analyst Review
Associate Director Kunal Singla suggests watching Suven Pharmaceuticals closely in May 2026. At Rs 1,250, Kunal Singla flags Pharmaceuticals – CDMO sector dynamics as the primary driver for SUVENPHAR’s near-term price action. He notes support in the Rs 1071 to Rs 1188 zone and flags any sustained close above Rs 1325 as a positive signal. Kunal Singla’s perspective on Suven Pharmaceuticals adds professional analysis to this Suven Pharmaceuticals analyst review and is not a buy recommendation.
Technical Analysis in This Suven Pharmaceuticals Analyst Review
At Rs 1,250, SUVENPHAR is trading within its 52-week band of Rs 1,050 to Rs 1,650. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 1071 to Rs 1188 band while resistance is seen in the Rs 1325 to Rs 1400 zone. A sustained move above Rs 1325 could open the path toward the analyst consensus target of Rs 1,550 as identified in this Suven Pharmaceuticals analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 1071 to Rs 1188 – investors tracking this Suven Pharmaceuticals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for SUVENPHAR.
- Resistance Zone: Rs 1325 to Rs 1400 – a sustained close above Rs 1325 would be a positive breakout signal worth flagging in this Suven Pharmaceuticals analyst review.
- Medium-Term Target: The analyst consensus of Rs 1,550 represents the base-case upside scenario in this Suven Pharmaceuticals analyst review.
Business Segment Analysis
CNS Molecule CDMO (Core High-Value Segment)
This is the primary revenue and margin driver for Suven Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 1,550.
Specialty API Custom Synthesis
This segment adds scale and diversification to Suven Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
Commercial Manufacturing Scale-Up Services
This represents the medium-term growth frontier for Suven Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Suven Pharmaceuticals Analyst Review
At Rs 1,250, Suven Pharmaceuticals trades at a trailing P/E of 45x. This Suven Pharmaceuticals analyst review presents three scenarios: a bull case of Rs 1,900 on strong earnings delivery, a base case of Rs 1,550 at analyst consensus, and a bear case of Rs 1,000 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Suven Pharmaceuticals analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 1,900 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 1,550 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 1,000 | Earnings miss or macro headwinds |
Trade Outlook for Suven Pharmaceuticals
Based on the technical and fundamental analysis in this Suven Pharmaceuticals analyst review, investors might watch SUVENPHAR near the support zone of Rs 1071 to Rs 1188 for potential opportunities. A flag above Rs 1325 could suggest improving momentum toward Rs 1,550. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Suven Pharmaceuticals in FY27
A well-rounded Suven Pharmaceuticals analyst review must assess downside risks. Key risks for Suven Pharmaceuticals include a macro slowdown affecting Pharmaceuticals – CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in SUVENPHAR.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Suven Pharmaceuticals Analyst Review Verdict for 2026
This Suven Pharmaceuticals analyst review concludes that at Rs 1,250, SUVENPHAR offers a defined risk-reward with a consensus target of Rs 1,550. The 52-week range of Rs 1,050 to Rs 1,650 provides context on the current entry point. Use this Suven Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on SUVENPHAR.
Frequently Asked Questions: Suven Pharmaceuticals Analyst Review 2026
What is the analyst target for Suven Pharmaceuticals in 2026?
The analyst consensus target is Rs 1,550, with a bull case of Rs 1,900 and a bear case of Rs 1,000. This Suven Pharmaceuticals analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Suven Pharmaceuticals a good investment at Rs 1,250?
At Rs 1,250 with a P/E of 45x and a consensus target of Rs 1,550, this Suven Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals – CDMO sector. Always consult a SEBI-registered advisor before investing.
What is Suven Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 1,650 and the 52-week low is Rs 1,050. At Rs 1,250, SUVENPHAR is positioned within this range as noted in this Suven Pharmaceuticals analyst review.
What are the key risks for Suven Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – CDMO sector as assessed in this Suven Pharmaceuticals analyst review.
Where can I track live data for Suven Pharmaceuticals?
Track Suven Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Suven Pharmaceuticals analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
